Hims & Hers Health (NYSE:HIMS) stock fell 4.1% in after-hours trading on Thursday following a Bloomberg report that revealed ...

The U.S. Federal Trade Commission is probing complaints about telehealth platform Hims & Hers regarding its advertising and ...

Telehealth and wellness platform Hims & Hers Health ($HIMS) recently disappointed investors with its mixed second-quarter ...

Telehealth company Hims & Hers Health’s (HIMS) business practices have been under investigation by the U.S. Federal Trade Commission (FTC) for over a year, Bloomberg reported. Following the news, HIMS ...

For more than a year, the Federal Trade Commission has been investigating Hims & Hers Health Inc.’s business practices, including whether it has made it too hard for customers to cancel subscriptions, ...

Hims & Hers Health (NYSE:HIMS) stock fell 5% in after-hours trading on Thursday following a Bloomberg report that revealed the Federal Trade Commission has been investigating the telehealth company’s ...

We recently published 10 Stocks That Vanished in Value Hims & Hers Health, Inc. (NYSE:HIMS) is one of the worst-performing ...

Insider moves in IonQ, Hims and Hers, Eli Lilly, and TransMedics reveal bold buys, record sales, and signals worth watching.

In Q2 2025, Hims & Hers reported adjusted earnings of $0.17 per share, topping estimates of $0.15. Revenue rose 73% year-over ...

Hims & Hers has been an incredible stock to own over the last few years, making shareholders rich. It has $2 billion in ...

Hims & Hers Health is upgraded to a speculative Buy after a 20% drop, with growth potential in GLP-1 sales outweighing key ...